International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan; Family Medicine Training Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, 700000, Viet Nam.
School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, 110, Taiwan.
Sleep Med Rev. 2023 Oct;71:101833. doi: 10.1016/j.smrv.2023.101833. Epub 2023 Aug 11.
Our systematic review and meta-analysis estimated the prevalence of post-COVID sleep disturbances in adult population. We systematically searched relevant studies from four databases that reported post-COVID sleep disturbances prevalence with a mean or median follow-up duration of ≥28 days. We identified 153 eligible papers, with a total COVID-19 population of 252437. Employing multilevel mixed-effects meta-analyses, we estimated the overall pooled prevalence of post-COVID sleep disturbances being 28.98% (25.73-32.34), with the highest prevalence reported in Europe and the lowest in Southeast Asia. Poor sleep quality was the most prevalent definition of sleep disturbances, followed by excessive daytime sleepiness, insomnia, sleep apnea. Prevalence estimates were notably higher when measured with Epworth sleepiness scale, or Pittsburgh sleep quality index compared to symptom questionnaires, self-reports, or personal interviews. Female sex (Odds ratio, OR = 1.59, 1.38-1.83) and severe/critical acute COVID-19 (OR = 1.36, 1.09-1.69) emerged as substantial risk factors. Our review underscore the persistent prevalence of sleep disturbances among COVID-19 survivors, and the importance of factors such as geography, definition, measures of sleep disorders, sex, and severity of acute COVID-19 infection. These findings highlight the urgent need for further investigation into the underlying molecular mechanisms driving these sleep disturbances to develop effective therapeutic strategies.
我们的系统评价和荟萃分析估计了成年人群中新冠后睡眠障碍的患病率。我们系统地从四个数据库中搜索了报告新冠后睡眠障碍患病率的相关研究,这些研究的平均或中位数随访时间≥28 天。我们确定了 153 篇符合条件的论文,其中 COVID-19 总人群为 252437 人。采用多水平混合效应荟萃分析,我们估计新冠后睡眠障碍的总体 pooled 患病率为 28.98%(25.73-32.34),其中欧洲报告的患病率最高,东南亚最低。睡眠质量差是睡眠障碍最常见的定义,其次是日间嗜睡、失眠、睡眠呼吸暂停。当使用 Epworth 嗜睡量表或匹兹堡睡眠质量指数测量时,患病率估计明显更高,而与症状问卷、自我报告或个人访谈相比。女性(优势比,OR=1.59,1.38-1.83)和严重/危重症急性 COVID-19(OR=1.36,1.09-1.69)是显著的危险因素。我们的综述强调了新冠幸存者中睡眠障碍的持续流行,以及地理位置、定义、睡眠障碍测量方法、性别和急性 COVID-19 感染严重程度等因素的重要性。这些发现突出表明,迫切需要进一步研究驱动这些睡眠障碍的潜在分子机制,以开发有效的治疗策略。